MTD vs. PCVX: Mettler-Toledo vs. Vaxcyte Stock Comparison

November 11, 2026

How do Mettler-Toledo (MTD) and Vaxcyte (PCVX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Mettler-Toledo (MTD) and Vaxcyte (PCVX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MTD is classified in Life Sciences Tools & Services while PCVX is classified in Biotechnology.

Mettler-Toledo (MTD) has more than two decades of public-market history since November 14, 1997, whereas Vaxcyte (PCVX) listed on June 12, 2020 and has a much shorter record to draw on.

Company profile comparison for Mettler-Toledo (MTD) and Vaxcyte (PCVX)
Profile Item	MTD	PCVX
Name	Mettler-Toledo International Inc.	Vaxcyte Inc.
Country/Region	Switzerland	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Biotechnology
GICS Sub-Industry	Life Sciences Tools & Services	Biotechnology
Market Capitalization	34.25 billion USD	10.11 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	November 14, 1997	June 12, 2020
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

MTD

PCVX

GSPC

Mettler-Toledo (MTD) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Mettler-Toledo (MTD) and Vaxcyte (PCVX). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Mettler-Toledo (MTD) and Vaxcyte (PCVX). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Mettler-Toledo (MTD) and Vaxcyte (PCVX)
Metric	MTD	PCVX
Total Return (1Y)	21.58%	59.00%
Total Return (3Y, Annualized)	19.54%	11.29%
Total Return (5Y, Annualized)	2.36%	21.60%

Risk Profile

Drawdown History

MTD

PCVX

GSPC

Mettler-Toledo (MTD) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Mettler-Toledo (MTD) and Vaxcyte (PCVX). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Mettler-Toledo (MTD) and Vaxcyte (PCVX)
Metric	MTD	PCVX
Volatility (1Y, Annualized)	31.70%	56.01%
Beta (5Y)	1.15	1.26
Max Drawdown (5Y)	-43.47%	-76.22%
Avg. Volume (3M)	197.80K	2.12M

Risk-Adjusted Performance

Risk-Return Positioning

MTD and PCVX are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Mettler-Toledo (MTD) and Vaxcyte (PCVX)
Metric	MTD	PCVX
Sharpe Ratio (1Y)	0.55	0.98
Sortino Ratio (1Y)	0.75	1.76

Profitability

ROE (TTM)

Mettler-Toledo (MTD) has no ROE value reported for this period; Vaxcyte (PCVX) reports a negative figure of -42.68%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
MTD: --

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-42.68%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
PCVX: -42.68%
Q1: -64.05%
Min: -167.77%

Mettler-Toledo (MTD) vs. Vaxcyte (PCVX): MTD does not report ROE, so it has no value marker; PCVX is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

Mettler-Toledo (MTD) at 22.25% converts revenue to bottom-line profit above its industry’s benchmark range, while Vaxcyte (PCVX) at 0.00% keeps roughly the typical share for its industry.

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.25%

MTD: 22.25%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
PCVX: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Mettler-Toledo (MTD) vs. Vaxcyte (PCVX): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Mettler-Toledo (MTD) at 28.70% operates in the top operating margin quartile, ahead of Vaxcyte (PCVX) at 0.00%, which runs around its industry’s norm.

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.70%

Max: 83.12%
MTD: 28.70%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 83.12%
Q3: 14.77%
PCVX: 0.00%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Mettler-Toledo (MTD) vs. Vaxcyte (PCVX): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Mettler-Toledo (MTD) and Vaxcyte (PCVX)
Metric	MTD	PCVX
ROE (TTM)	--	-42.68%
ROA (TTM)	20.09%	-24.98%
Net Margin (TTM)	22.25%	0.00%
Operating Margin (TTM)	28.70%	0.00%
Gross Margin (TTM)	59.16%	0.00%

Growth

Revenue Growth

Only one side can be read here: Mettler-Toledo (MTD) reports revenue growth of 3.98%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.

Mettler-Toledo (MTD) vs. Vaxcyte (PCVX): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Mettler-Toledo (MTD) reports EPS growth of 3.88%, ranked against its industry; Vaxcyte (PCVX) has no EPS growth figure this period.

Mettler-Toledo (MTD) vs. Vaxcyte (PCVX): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Mettler-Toledo (MTD) and Vaxcyte (PCVX)
Metric	MTD	PCVX
Revenue Growth (YoY)	3.98%	--
Revenue Growth (3Y CAGR)	0.90%	--
EPS Growth (YoY)	3.88%	--
EPS Growth (3Y CAGR)	3.06%	--

Financial Strength

Current Ratio (MRQ)

Vaxcyte (PCVX) at 4.56 keeps current ratio within its industry’s typical mid-range, while Mettler-Toledo (MTD) at 1.10 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MTD.

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.10

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
MTD: 1.10
Min: 0.10

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.56

Max: 25.13
Q3: 12.13
Median: 5.52
PCVX: 4.56
Q1: 2.47
Min: 0.10

Mettler-Toledo (MTD) vs. Vaxcyte (PCVX): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Vaxcyte (PCVX) at 0.09 is near its industry mid-range for debt-to-equity ratio, while Mettler-Toledo (MTD) at 26.06 sits above its benchmark range, pointing to a heavier debt load relative to equity.

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.06

MTD: 26.06
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max: 1.42
Q3: 0.65
Median: 0.15
PCVX: 0.09
Q1: 0.02
Min: 0.00

Mettler-Toledo (MTD) vs. Vaxcyte (PCVX): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Mettler-Toledo (MTD) and Vaxcyte (PCVX)
Metric	MTD	PCVX
Current Ratio (MRQ)	1.10	4.56
Debt / Equity (MRQ)	26.06	0.09
Net Debt / EBITDA	1.58	--

Dividends

Dividend Yield (TTM)

Neither Mettler-Toledo (MTD) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MTD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Mettler-Toledo (MTD) vs. Vaxcyte (PCVX): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Mettler-Toledo (MTD) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MTD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Mettler-Toledo (MTD) vs. Vaxcyte (PCVX): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Mettler-Toledo (MTD) and Vaxcyte (PCVX)
Metric	MTD	PCVX
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Mettler-Toledo (MTD) trades at 37.38 times trailing earnings, ranked against its peers, while Vaxcyte (PCVX) has no P/E ratio this period.

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

37.38

Max: 85.34
Q3: 43.46
MTD: 37.38
Median: 26.69
Q1: 13.30
Min: 0.07

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
PCVX: --

Mettler-Toledo (MTD) vs. Vaxcyte (PCVX): PCVX does not report P/E ratio, so it has no value marker; MTD is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

A sales-based read is only available for Mettler-Toledo (MTD), whose P/S ratio of 8.16 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.16

Max: 58.18
Q3: 25.77
MTD: 8.16
Median: 7.30
Q1: 3.01
Min: 0.01

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01
PCVX: --

Mettler-Toledo (MTD) vs. Vaxcyte (PCVX): PCVX does not report P/S ratio, so it has no value marker; MTD is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

Vaxcyte (PCVX) at 3.83 sits near its industry’s typical P/B ratio, while Mettler-Toledo (MTD) at 442.71 prices above its benchmark range — MTD looks rich relative to book.

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

442.71

MTD: 442.71
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.83

Max: 13.53
Q3: 6.54
PCVX: 3.83
Median: 3.25
Q1: 1.69
Min: -5.59

Mettler-Toledo (MTD) vs. Vaxcyte (PCVX): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Mettler-Toledo (MTD) and Vaxcyte (PCVX)
Metric	MTD	PCVX
P/E Ratio (TTM)	37.38	--
P/S Ratio (TTM)	8.16	--
P/B Ratio (MRQ)	442.71	3.83
Free Cash Flow Yield (TTM)	1.97%	-5.24%